Incidence of Acute Renal Failure in Patients Using Levetiracetam Versus Other Antiseizure Medications: A Voluntary Post-Authorization Safety Study

Raphaelle Beau-Lejdstrom (), Lai San Hong, Xabier Garcia de Albeniz, Florin Floricel, Johan Lorenzen, Francois Bonfitto, Linda Kalilani, Christian Loesch, Graham Luscombe, Susana Perez-Gutthann, Isabelle Mottet and Nadia Foskett
Additional contact information
Raphaelle Beau-Lejdstrom: UCB Pharma
Lai San Hong: Redsen Limited
Xabier Garcia de Albeniz: RTI Health Solutions
Florin Floricel: UCB Pharma
Johan Lorenzen: University Hospital Zurich
Francois Bonfitto: UCB Pharma
Linda Kalilani: UCB Pharma
Christian Loesch: UCB Pharma
Graham Luscombe: UCB Pharma
Susana Perez-Gutthann: RTI Health Solutions
Isabelle Mottet: UCB Pharma
Nadia Foskett: UCB Pharma

Drug Safety, 2022, vol. 45, issue 7, No 8, 790 pages

Abstract: Abstract Introduction Acute kidney injury is an expected adverse drug reaction listed in the European Union (EU) Summary of Product Characteristics (SmPC) for levetiracetam, one of the most widely used modern antiseizure medications (ASMs). Objective We conducted a voluntary post-authorization safety study to characterize the rate of acute renal failure (ARF) in patients exposed to levetiracetam versus other ASMs. Methods New users of ASMs without prior renal dysfunction were identified and followed for 30 days in the IBM® MarketScan® database (USA, January 2008–December 2017). ARF was defined as a diagnosis on inpatient or emergency department claims. We estimated adjusted incidence rates, incidence rate ratios (IRRs), and incidence rate differences (IRDs) of ARF in patients initiating levetiracetam versus other ASMs. Results Overall, 110,336 patients were eligible for the monotherapy cohort and 96,215 were eligible for the polytherapy cohort. The overall crude rate of ARF following a new ASM was 6.0 and 6.5 per 10,000 patients for the ‘monotherapy’ and ‘polytherapy’ cohorts, respectively, in the first 30 days after the index date. In the monotherapy cohort, the IRR for ARF was 1.37 (95% confidence interval [CI] 0.80–2.34) and the corresponding IRD was 2.0 (95% CI − 1.12 to 5.12) additional ARFs per 10,000 patient-months. In the polytherapy cohort, the adjusted IRR for ARF was 0.94 (95% CI 0.51–1.74) and the corresponding IRD was − 0.42 cases per 10,000 patient-months (95% CI − 4.01 to 3.17). Conclusions The rate of ARFs in ASM new users was very low. In patients without prior ASMs, the estimated difference in risk of ARF associated with initiation of levetiracetam versus initiation of other ASMs was small, with 95% CIs compatible with small protective or harmful effects. In patients receiving polytherapy, the difference was compatible with the null and the 95% CI with small protective or harmful effects.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-022-01193-0 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:45:y:2022:i:7:d:10.1007_s40264-022-01193-0

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-022-01193-0

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().